Vical Inc (VICL) 1.28 $VICL
Vical Reports Second Quarter 2014 Financial Results and Progress in Key Development Programs
GlobeNewswire - Thu Jul 31, 5:01AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and six months ended June 30, 2014. The net loss for the second quarter of 2014 was $4.0 million, or $0.05 per share, compared with a net loss of $9.9 million, or $0.11 per share, for the second quarter of 2013. Revenues for the second quarter of 2014 were $4.5 million, compared with revenues of $1.5 million for the second quarter of 2013, reflecting higher revenues from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
WEALTHMAKERS.COM Issues Bearish Research Reports on SLAB, TAP, TEAR, UAN, VICL, VSAT
M2 - Wed Jul 30, 9:44AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Silicon Laboratories Inc (NASDAQ:SLAB), Molson Coors Brewing Co (NYSE:TAP), Tearlab Corp (NASDAQ:TEAR), CVR Partners LP (NYSE:UAN), Vical Inc (NASDAQ:VICL), VIASAT, INC. (NASDAQ:VSAT)
Vical Announces News Release and Conference Call Schedule for Second Quarter 2014 Financial Results
GlobeNewswire - Thu Jul 24, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three and six months ended June 30, 2014, before the opening of trading on Thursday, July 31, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, July 31. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
Biotech Stocks Scanner -- Regeneron Pharma, BioCryst Pharma, Spectrum Pharma, Exact Sciences, and Vical Inc.
PR Newswire - Mon Jul 21, 8:10AM CDT
On Friday, July 18, 2014, the NASDAQ Composite ended at 4,432.15, up 1.57%, the Dow Jones Industrial Average finished the day 0.73% higher at 17,100.18, and the S&P 500 closed at 1,978.22, up 1.03%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 710.68, up 1.63%, and the index has advanced 6.63% in the previous three months. Investor-Edge has initiated coverage on the following equities: Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Exact Sciences Corporation (NASDAQ: EXAS), and Vical Inc. (NASDAQ: VICL). Free research on these five companies can be accessed at:
5 Stocks Under $10 Set to Soar
at The Street - Fri Jul 18, 7:40AM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
XenoPort's XP23829 in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 3:52PM CDT
XenoPort, Inc. (XNPT) has commenced a phase II study on XP23829 for moderate-to-severe chronic plaque-type psoriasis.
2014 Report of the International Therapeutic Vaccines Market - Forecasts to 2018
M2 - Wed Jun 18, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4s9wr9/global) has announced the addition of the "2014 Report of the International Therapeutic Vaccines Market - Forecasts to 2018" report to their offering. A therapeutic vaccine is a biological combination developed to improve immunity by inducing an attack against a diseased cell or tissue. This differs from prophylactic vaccines, which are administered to an individual with a disease in order to induce a defense mechanism. There are two approved cancer therapeutic vaccines on the market; Provenge and Oncophage. Additionally, a large number of therapeutic vaccines are under clinical development and are expected to be approved for use during the forecast period. The analysts forecast the Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Therapeutic Vaccine market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapeutic vaccines available in the market. The report, 2014 Report of the International Therapeutic Vaccines Market - Forecasts to 2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Therapeutic Vaccines market landscape and its growth prospects in the coming years. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Geographical Segmentation 08. Key Leading Countries 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Pipeline Analysis 17. Vendor Landscape 18. Key Vendor Analysis Companies Mentioned: - Agenus - Bavarian - Dendreon - GlaxoSmithKline - Novartis International - AFFiRiS - Argos Therapeutics - Celldex Therapeutics - CEL-SCI - Cytos Biotechnology - GlobeImmune - NewLink Genetics - NovaRx - Oncothyreon - TVAX Biomedical - TapImmune - Vical - Vaccinogen For more information visit http://www.researchandmarkets.com/research/4s9wr9/global
Vical to Present at the JMP Securities Annual Healthcare Conference
GlobeNewswire - Wed Jun 18, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, June 25, at 12:30 p.m. ET at the JMP Securities Healthcare Conference 2014 (New York, June 24 - 25). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
Analyst Scanner on Health Care Sector Equities -- Research on Vical, VCA Inc., TherapeuticsMD, and Theravance
PR Newswire - Mon Jun 16, 7:00AM CDT
The trading session on Friday, June 13, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,775.74, up 0.25% and the NASDAQ Composite closed at 4,310.65, up 0.30%. The S&P 500 finished the day 0.31% higher at 1,936.16. The gains were broad based as nine out of the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 688.44, down 0.02%, while the index has gained 2.46% in the previous one month. Investor-Edge has initiated coverage on the following equities: Vical Inc. (NASDAQ: VICL), VCA Inc. (NASDAQ: WOOF), TherapeuticsMD Inc. (NYSE MKT: TXMD) and Theravance Inc. (NASDAQ: THRX). Free technical research on VICL, WOOF, TXMD and THRX can be downloaded upon signing up at:
Measles - Pipeline Review, H1 2014
M2 - Tue Jun 10, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zbxjcr/measles) has announced the addition of the "Measles - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Measles, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Measles and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Vical Incorporated - GlaxoSmithKline plc - Zydus Cadila Healthcare Limited - LG Life Sciences, Ltd. - Cadila Pharmaceuticals Ltd. - Beijing Tiantan Biological Products Co., Ltd. - VBI Vaccines - Serum Institute of India Limited - China Biologic Products, Inc. - Universal Stabilization Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/zbxjcr/measles
4 Stocks Under $10 Making Big Moves
at The Street - Fri May 30, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Provectus Executive Actions Worthy of FDA, SEC Investigations
at The Street - Tue May 27, 5:00AM CDT
Provectus Chief Operating Officer Peter Culpepper made several unsubstantiated claims about the efficacy and safety of PV-10 in melanoma patients on a conference call Friday evening.
Marrone Bio Innovations Hires VP of Technology Development
GlobeNewswire - Wed Mar 26, 8:00AM CDT
Marrone Bio Innovations, Inc. (MBI) (Nasdaq:MBII), a leading global provider of bio-based pest management and plant health products announced it has hired Amit Vasavada, Ph.D., as Vice President of Technology Development, a newly created position within the company. Dr. Vasavada brings 30 years of experience in industrial bioproducts, fermentation R&D and manufacturing, process engineering, and technology transfer to MBI. His broad commercial background includes positions with General Atomics, Vical Inc., Diversa Corporation, Monsanto (CP Kelco), and Chiron Corp.
3 Stocks Under $10 Moving Higher
at The Street - Fri Mar 21, 5:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Why Vical (VICL) Might Be a Diamond in the Rough? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:46AM CDT
Vical has seen loss estimates narrowing over the past month and looks well positioned for a solid gain
Vical to Present at the ROTH Capital Partners 26th Annual Growth Stock Conference
GlobeNewswire - Wed Mar 05, 3:06PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, March 12, at 8:30 a.m. PDT at the ROTH Capital Partners 26th Annual Growth Stock Conference (Newport Beach, California March 9 - 12). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
Vical to Present at the 34th Annual Cowen Health Care Conference
GlobeNewswire - Wed Feb 26, 3:09PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Monday, March 3, at 2:10 p.m. ET at the 34 Annual Cowen Health Care Conference (Boston, Massachusetts March 3 - 5).
Vical Q4 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 11:10AM CST
Vical's fourth quarter loss narrows
Hot Stock: Vical, Shares Gain 14.7% (VICL)
Comtex SmarTrend(R) - Wed Feb 12, 10:11AM CST
Vical (NASDAQ:VICL) is one of today's best performing low-priced stocks, up 14.7% to $1.56 on 1.6x average daily volume. Thus far today, Vical has traded 3.4 million shares, vs. average volume of 2.2 million shares per day. The stock has outperformed the Dow (14.7% to the Dow's -0.2%) and outperformed the S&P 500 (14.7% to the S&P's -0.0%) during today's trading.
Vical Reports 2013 Financial Results and Progress in Key Development Programs
GlobeNewswire - Wed Feb 12, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today reported financial results for the year ended December 31, 2013. The net loss for 2013 was $31.2 million, or $0.36 per share, compared with a net loss of $22.9 million, or $0.27 per share, for 2012. Revenues for 2013 were $7.7 million, compared with revenues of $17.5 million for 2012, reflecting lower payments from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
Vical Reports Second Quarter 2014 Financial Results and Progress in Key Development Programs
GlobeNewswire - Thu Jul 31, 5:01AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and six months ended June 30, 2014. The net loss for the second quarter of 2014 was $4.0 million, or $0.05 per share, compared with a net loss of $9.9 million, or $0.11 per share, for the second quarter of 2013. Revenues for the second quarter of 2014 were $4.5 million, compared with revenues of $1.5 million for the second quarter of 2013, reflecting higher revenues from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
WEALTHMAKERS.COM Issues Bearish Research Reports on SLAB, TAP, TEAR, UAN, VICL, VSAT
M2 - Wed Jul 30, 9:44AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Silicon Laboratories Inc (NASDAQ:SLAB), Molson Coors Brewing Co (NYSE:TAP), Tearlab Corp (NASDAQ:TEAR), CVR Partners LP (NYSE:UAN), Vical Inc (NASDAQ:VICL), VIASAT, INC. (NASDAQ:VSAT)
Vical Announces News Release and Conference Call Schedule for Second Quarter 2014 Financial Results
GlobeNewswire - Thu Jul 24, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three and six months ended June 30, 2014, before the opening of trading on Thursday, July 31, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, July 31. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
Biotech Stocks Scanner -- Regeneron Pharma, BioCryst Pharma, Spectrum Pharma, Exact Sciences, and Vical Inc.
PR Newswire - Mon Jul 21, 8:10AM CDT
On Friday, July 18, 2014, the NASDAQ Composite ended at 4,432.15, up 1.57%, the Dow Jones Industrial Average finished the day 0.73% higher at 17,100.18, and the S&P 500 closed at 1,978.22, up 1.03%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 710.68, up 1.63%, and the index has advanced 6.63% in the previous three months. Investor-Edge has initiated coverage on the following equities: Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Exact Sciences Corporation (NASDAQ: EXAS), and Vical Inc. (NASDAQ: VICL). Free research on these five companies can be accessed at:
5 Stocks Under $10 Set to Soar
at The Street - Fri Jul 18, 7:40AM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
XenoPort's XP23829 in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 3:52PM CDT
XenoPort, Inc. (XNPT) has commenced a phase II study on XP23829 for moderate-to-severe chronic plaque-type psoriasis.
2014 Report of the International Therapeutic Vaccines Market - Forecasts to 2018
M2 - Wed Jun 18, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4s9wr9/global) has announced the addition of the "2014 Report of the International Therapeutic Vaccines Market - Forecasts to 2018" report to their offering. A therapeutic vaccine is a biological combination developed to improve immunity by inducing an attack against a diseased cell or tissue. This differs from prophylactic vaccines, which are administered to an individual with a disease in order to induce a defense mechanism. There are two approved cancer therapeutic vaccines on the market; Provenge and Oncophage. Additionally, a large number of therapeutic vaccines are under clinical development and are expected to be approved for use during the forecast period. The analysts forecast the Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Therapeutic Vaccine market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapeutic vaccines available in the market. The report, 2014 Report of the International Therapeutic Vaccines Market - Forecasts to 2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Therapeutic Vaccines market landscape and its growth prospects in the coming years. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Geographical Segmentation 08. Key Leading Countries 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Pipeline Analysis 17. Vendor Landscape 18. Key Vendor Analysis Companies Mentioned: - Agenus - Bavarian - Dendreon - GlaxoSmithKline - Novartis International - AFFiRiS - Argos Therapeutics - Celldex Therapeutics - CEL-SCI - Cytos Biotechnology - GlobeImmune - NewLink Genetics - NovaRx - Oncothyreon - TVAX Biomedical - TapImmune - Vical - Vaccinogen For more information visit http://www.researchandmarkets.com/research/4s9wr9/global
Vical to Present at the JMP Securities Annual Healthcare Conference
GlobeNewswire - Wed Jun 18, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, June 25, at 12:30 p.m. ET at the JMP Securities Healthcare Conference 2014 (New York, June 24 - 25). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
Analyst Scanner on Health Care Sector Equities -- Research on Vical, VCA Inc., TherapeuticsMD, and Theravance
PR Newswire - Mon Jun 16, 7:00AM CDT
The trading session on Friday, June 13, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,775.74, up 0.25% and the NASDAQ Composite closed at 4,310.65, up 0.30%. The S&P 500 finished the day 0.31% higher at 1,936.16. The gains were broad based as nine out of the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 688.44, down 0.02%, while the index has gained 2.46% in the previous one month. Investor-Edge has initiated coverage on the following equities: Vical Inc. (NASDAQ: VICL), VCA Inc. (NASDAQ: WOOF), TherapeuticsMD Inc. (NYSE MKT: TXMD) and Theravance Inc. (NASDAQ: THRX). Free technical research on VICL, WOOF, TXMD and THRX can be downloaded upon signing up at:
Measles - Pipeline Review, H1 2014
M2 - Tue Jun 10, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zbxjcr/measles) has announced the addition of the "Measles - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Measles, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Measles and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Vical Incorporated - GlaxoSmithKline plc - Zydus Cadila Healthcare Limited - LG Life Sciences, Ltd. - Cadila Pharmaceuticals Ltd. - Beijing Tiantan Biological Products Co., Ltd. - VBI Vaccines - Serum Institute of India Limited - China Biologic Products, Inc. - Universal Stabilization Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/zbxjcr/measles
4 Stocks Under $10 Making Big Moves
at The Street - Fri May 30, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Provectus Executive Actions Worthy of FDA, SEC Investigations
at The Street - Tue May 27, 5:00AM CDT
Provectus Chief Operating Officer Peter Culpepper made several unsubstantiated claims about the efficacy and safety of PV-10 in melanoma patients on a conference call Friday evening.
Marrone Bio Innovations Hires VP of Technology Development
GlobeNewswire - Wed Mar 26, 8:00AM CDT
Marrone Bio Innovations, Inc. (MBI) (Nasdaq:MBII), a leading global provider of bio-based pest management and plant health products announced it has hired Amit Vasavada, Ph.D., as Vice President of Technology Development, a newly created position within the company. Dr. Vasavada brings 30 years of experience in industrial bioproducts, fermentation R&D and manufacturing, process engineering, and technology transfer to MBI. His broad commercial background includes positions with General Atomics, Vical Inc., Diversa Corporation, Monsanto (CP Kelco), and Chiron Corp.
3 Stocks Under $10 Moving Higher
at The Street - Fri Mar 21, 5:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Why Vical (VICL) Might Be a Diamond in the Rough? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:46AM CDT
Vical has seen loss estimates narrowing over the past month and looks well positioned for a solid gain
Vical to Present at the ROTH Capital Partners 26th Annual Growth Stock Conference
GlobeNewswire - Wed Mar 05, 3:06PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, March 12, at 8:30 a.m. PDT at the ROTH Capital Partners 26th Annual Growth Stock Conference (Newport Beach, California March 9 - 12). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
Vical to Present at the 34th Annual Cowen Health Care Conference
GlobeNewswire - Wed Feb 26, 3:09PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Monday, March 3, at 2:10 p.m. ET at the 34 Annual Cowen Health Care Conference (Boston, Massachusetts March 3 - 5).
Vical Q4 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 11:10AM CST
Vical's fourth quarter loss narrows
Hot Stock: Vical, Shares Gain 14.7% (VICL)
Comtex SmarTrend(R) - Wed Feb 12, 10:11AM CST
Vical (NASDAQ:VICL) is one of today's best performing low-priced stocks, up 14.7% to $1.56 on 1.6x average daily volume. Thus far today, Vical has traded 3.4 million shares, vs. average volume of 2.2 million shares per day. The stock has outperformed the Dow (14.7% to the Dow's -0.2%) and outperformed the S&P 500 (14.7% to the S&P's -0.0%) during today's trading.
Vical Reports 2013 Financial Results and Progress in Key Development Programs
GlobeNewswire - Wed Feb 12, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today reported financial results for the year ended December 31, 2013. The net loss for 2013 was $31.2 million, or $0.36 per share, compared with a net loss of $22.9 million, or $0.27 per share, for 2012. Revenues for 2013 were $7.7 million, compared with revenues of $17.5 million for 2012, reflecting lower payments from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
